Smart Financial Automation for Businesses
File upload
Model comparison
Surprise Me!
Blog creation
Effortlessly crafted, personalized
financial blog.
Asset report
AI PB delivers
hyper-personalized
asset reports instantly
AI stock summary
Creating stock
summaries using
diverse data sources
Stock report
Stock report drafts
at your fingertips
with a single search
File upload
Model comparison
Surprise Me!
Blog creation
Effortlessly crafted, personalized
financial blog.
Asset report
AI PB delivers
hyper-personalized
asset reports instantly
AI stock summary
Creating stock
summaries using
diverse data sources
Stock report
Stock report drafts
at your fingertips
with a single search
Expert Predictions on Jerome Powell's 2024 Jackson Hole Economic Policy Symposium Speech
Brochure
Learn More About Our Solution!
Learn More About Our Solution!
Learn More About Our Solution!
Download our latest solution brochure
Features
Our Key Features
Our Key Features
OLA Financial Chatbot
Real-time Answers: Provides instant, accurate insights using live financial data.
Real-time Answers: Provides instant, accurate insights using live financial data.
Real-time Answers: Provides instant, accurate insights using live financial data.
Always Up-to-date: Tracks news every 20 minutes to recommend relevant questions.
Always Up-to-date: Tracks news every 20 minutes to recommend relevant questions.
Always Up-to-date: Tracks news every 20 minutes to recommend relevant questions.
Customizable Integration: Seamlessly fits into your apps via API or on-premise deployment.
Customizable Integration: Seamlessly fits into your apps via API or on-premise deployment.
Customizable Integration: Seamlessly fits into your apps via API or on-premise deployment.
Is there a recent report available on Rigachem Bio?
Rigachem Bio closed at 104,800 won, down 0.10% from the previous day.
On September 20, 2024, Eugene Investment & Securities published the following report on Rigachem Bio:
1. Rigachem Bio's LCB84 is expected to confirm its potential as a best-in-class treatment through interim results from Phase 1 clinical trials in 2025.
The company has secured a large-scale funding of 500 billion won through Orion's investment in 2024, accelerating its research and development efforts.
Additionally, two more pipelines are expected to enter global Phase 1 clinical trials starting in 2025.
Rigachem Bio currently holds the largest number of research and development pipelines among global ADC treatment developers.
The investment opinion is rated as BUY, with a target price of 140,000 won, maintaining its position as a top pick within the biotech sector.
...
Is there a recent report available on Rigachem Bio?
Rigachem Bio closed at 104,800 won, down 0.10% from the previous day.
On September 20, 2024, Eugene Investment & Securities published the following report on Rigachem Bio:
1. Rigachem Bio's LCB84 is expected to confirm its potential as a best-in-class treatment through interim results from Phase 1 clinical trials in 2025.
The company has secured a large-scale funding of 500 billion won through Orion's investment in 2024, accelerating its research and development efforts.
Additionally, two more pipelines are expected to enter global Phase 1 clinical trials starting in 2025.
Rigachem Bio currently holds the largest number of research and development pipelines among global ADC treatment developers.
The investment opinion is rated as BUY, with a target price of 140,000 won, maintaining its position as a top pick within the biotech sector.
...
Is there a recent report available on Rigachem Bio?
Rigachem Bio closed at 104,800 won, down 0.10% from the previous day.
On September 20, 2024, Eugene Investment & Securities published the following report on Rigachem Bio:
1. Rigachem Bio's LCB84 is expected to confirm its potential as a best-in-class treatment through interim results from Phase 1 clinical trials in 2025.
The company has secured a large-scale funding of 500 billion won through Orion's investment in 2024, accelerating its research and development efforts.
Additionally, two more pipelines are expected to enter global Phase 1 clinical trials starting in 2025.
Rigachem Bio currently holds the largest number of research and development pipelines among global ADC treatment developers.
The investment opinion is rated as BUY, with a target price of 140,000 won, maintaining its position as a top pick within the biotech sector.
...
Up-To-Date
Financial Data
Asset & Stock Report Automation
Asset & Stock Report Automation
Daily Asset Reports: Automatically generate personalized reports using live data.
Daily Asset Reports: Automatically generate personalized reports using live data.
Daily Asset Reports: Automatically generate personalized reports using live data.
Stock Reports on Demand: Use templates to quickly create stock reports, saving time and ensuring accuracy.
Stock Reports on Demand: Use templates to quickly create stock reports, saving time and ensuring accuracy.
Stock Reports on Demand: Use templates to quickly create stock reports, saving time and ensuring accuracy.
2024.07.19
Investment Opinion (Maintain):
Buy
Target Price (Maintain)
USD 128
Current Price (24/07/17)
USD 95.08
Upside Potential
34.6%
S&P 500(p)
5,588.27
EPS Growth Rate
-50.6
P/E(24F.x)
13.9
Dividend Yield(%)
1.4
Market Capitalization
10.82
Number of Issued Shares
117.5
Float Ratio
64.3
Beta (12M) Daily Return
0.87
52-Week Low (KRW)
90.47
52-Week High (KRW)
232.52
(%)
1M
6M
12M
Absolute Price
-2.0
-2.5
-18.4
Absolute Price
-2.0
-2.5
-18.4
ALB US
NYSE
The Last One Standing
2024 Outlook
The revenue for 2024 is projected to be $5.6bn (-42% YoY), with adjusted EBITDA estimated at $1.0bn (-63% YoY). According to the aforementioned price band chart, the adjusted EBITDA for the lithium segment is expected to be around $0.7bn to $0.8bn in 2024, $0.8bn to $0.9bn in 2025, and $1.0bn to $1.1bn in 2026.
The target price was derived by applying a Target EV/EBITDA multiple of 13x to the 2025 EBITDA of $1.5bn. The Target EV/EBITDA is based on the average value of major global lithium producers. We believe the company is well-positioned to survive in the competitive market due to 1) cost competitiveness of its resource base, 2) volume assurance through capacity adjustments, and 3) stable operations in its non-lithium business segments.
Albemarle’s abundant resources and high-quality assets are noteworthy. The unit cash cost from its brine resources is approximately $1,900 per ton, which is about 4.7 times lower than the cost of lithium production from Chinese lepidolite regions. Additionally, the company’s diverse product portfolio, underpinned by the vast quantity and superior quality of its resources, is a key attraction. The company’s adherence to its mid-to-long-term strategy is a significant point of focus. Despite a downward trend in battery metal prices, Albemarle is operating its existing projects stably and gradually expanding its production capacity, thus setting the groundwork for long-term success. The lithium production volume from its projects is expected to increase by approximately 20-25% by 2025
ALB US
NYSE
The Last One Standing
2024 Outlook
The revenue for 2024 is projected to be $5.6bn (-42% YoY), with adjusted EBITDA estimated at $1.0bn (-63% YoY). According to the aforementioned price band chart, the adjusted EBITDA for the lithium segment is expected to be around $0.7bn to $0.8bn in 2024, $0.8bn to $0.9bn in 2025, and $1.0bn to $1.1bn in 2026.
The target price was derived by applying a Target EV/EBITDA multiple of 13x to the 2025 EBITDA of $1.5bn. The Target EV/EBITDA is based on the average value of major global lithium producers. We believe the company is well-positioned to survive in the competitive market due to 1) cost competitiveness of its resource base, 2) volume assurance through capacity adjustments, and 3) stable operations in its non-lithium business segments.
Albemarle’s abundant resources and high-quality assets are noteworthy. The unit cash cost from its brine resources is approximately $1,900 per ton, which is about 4.7 times lower than the cost of lithium production from Chinese lepidolite regions. Additionally, the company’s diverse product portfolio, underpinned by the vast quantity and superior quality of its resources, is a key attraction. The company’s adherence to its mid-to-long-term strategy is a significant point of focus. Despite a downward trend in battery metal prices, Albemarle is operating its existing projects stably and gradually expanding its production capacity, thus setting the groundwork for long-term success. The lithium production volume from its projects is expected to increase by approximately 20-25% by 2025
2024.07.19
Investment Opinion (Maintain):
Buy
Target Price (Maintain)
USD 128
Current Price (24/07/17)
USD 95.08
Upside Potential
34.6%
S&P 500(p)
5,588.27
EPS Growth Rate
-50.6
P/E(24F.x)
13.9
Dividend Yield(%)
1.4
Market Capitalization
10.82
Number of Issued Shares
117.5
Float Ratio
64.3
Beta (12M) Daily Return
0.87
52-Week Low (KRW)
90.47
52-Week High (KRW)
232.52
(%)
1M
6M
12M
Absolute Price
-2.0
-2.5
-18.4
Absolute Price
-2.0
-2.5
-18.4
ALB US
NYSE
The Last One Standing
2024 Outlook
The revenue for 2024 is projected to be $5.6bn (-42% YoY), with adjusted EBITDA estimated at $1.0bn (-63% YoY). According to the aforementioned price band chart, the adjusted EBITDA for the lithium segment is expected to be around $0.7bn to $0.8bn in 2024, $0.8bn to $0.9bn in 2025, and $1.0bn to $1.1bn in 2026.
The target price was derived by applying a Target EV/EBITDA multiple of 13x to the 2025 EBITDA of $1.5bn. The Target EV/EBITDA is based on the average value of major global lithium producers. We believe the company is well-positioned to survive in the competitive market due to 1) cost competitiveness of its resource base, 2) volume assurance through capacity adjustments, and 3) stable operations in its non-lithium business segments.
Albemarle’s abundant resources and high-quality assets are noteworthy. The unit cash cost from its brine resources is approximately $1,900 per ton, which is about 4.7 times lower than the cost of lithium production from Chinese lepidolite regions. Additionally, the company’s diverse product portfolio, underpinned by the vast quantity and superior quality of its resources, is a key attraction. The company’s adherence to its mid-to-long-term strategy is a significant point of focus. Despite a downward trend in battery metal prices, Albemarle is operating its existing projects stably and gradually expanding its production capacity, thus setting the groundwork for long-term success. The lithium production volume from its projects is expected to increase by approximately 20-25% by 2025
Streamline recurring
reports with ease.
Streamline recurring
reports with ease.
Streamline recurring
reports with ease.
B2B Solutions Tailored for Enterprises
B2B Solutions Tailored for Enterprises
B2B Solutions Tailored for Enterprises
OLA helps financial institutions, investment firms, and fintechs automate processes and boost efficiency with AI-driven reports, content generation, and secure on-premise solutions—seamlessly fitting into your existing systems.
Why Us?
Why Choose OLA?
Why Choose OLA?
We aim to boost profitability with
smarter automation and actionable data.
Reduce
Costs
Reduce
Costs
Reduce
Costs
Automate financial content and save labor costs equivalent to one team member.
Increase
Retention
Increase
Retention
Increase
Retention
Deliver personalized messages that keep customers engaged.
Boost Trading Activity
Boost Trading Activity
Boost Trading Activity
Provide timely insights to increase trade volume and frequency.
Stay Ahead!
Leverage up-to-date data
to gain a competitive edge.
FAQ
Frequently Asked Questions
Frequently Asked Questions
What is OLA?
Who can benefit from OLA?
What types of reports can OLA generate?
Can OLA integrate with existing systems?
Is the chatbot customizable?
How secure is OLA’s service?
What is OLA?
Who can benefit from OLA?
What types of reports can OLA generate?
Can OLA integrate with existing systems?
Is the chatbot customizable?
How secure is OLA’s service?
What is OLA?
Who can benefit from OLA?
What types of reports can OLA generate?
Can OLA integrate with existing systems?
Is the chatbot customizable?
How secure is OLA’s service?
Contact
Let's Connect!
Let's Connect!
Curious about how OLA can accelerate your business?
Leave us your details, and we’ll reach out soon.
OneLineAI
OneLineAI
OneLineAI
OLA is an AI-powered financial content creation and chatbot solution, delivering real-time insights, automated reports, and customizable tools to enhance business efficiency and customer engagement.
OLA is an AI-powered financial content creation and chatbot solution, delivering real-time insights, automated reports, and customizable tools to enhance business efficiency and customer engagement.
OLA is an AI-powered financial content creation and chatbot solution, delivering real-time insights, automated reports, and customizable tools to enhance business efficiency and customer engagement.
© 2024 OneLineAI. All Rights Reserved. Made with ☕, 🍔, and lots of ❤️.
© 2024 OneLineAI. All Rights Reserved.
Created with ☕, 🍔 and a lot of ❤️.
© 2024 OneLineAI. All Rights Reserved.
Created with ☕, 🍔 and a lot of ❤️.